Beyond the P Value: A Systematic Framework for Interpreting Oncology Clinical Trials

Area of Science:

• Oncology
• Clinical Trial Design
• Biostatistics

Background:

• Interpreting oncology clinical trials solely by statistical significance (P < .05) can lead to misclassification of therapies.
• This binary approach risks abandoning effective treatments or pursuing futile ones, impacting resource allocation.

Purpose of the Study:

• To develop a structured framework for evaluating late-phase oncology trials beyond P values.
• To provide a systematic methodology for the post hoc assessment of negative clinical trial results.

Main Methods:

• A critical review of relevant literature and landmark late-phase oncology trials.
• Analysis of common failure mechanisms and methodological pitfalls in clinical trials.
• Construction of a three-step framework: classification, diagnosis, and recommendations.

Main Results:

• The framework categorizes trials into five types: true negatives, false negatives, inconclusive, positive but irrelevant, and nonsuperior but valuable.
• Diagnosis involves root-cause analysis of design flaws, biases, or statistical issues.
• Recommendations include trial redesign, biomarker validation, precision medicine, or confirming futility.

Conclusions:

• This framework enables a nuanced, value-based interpretation of trial outcomes, moving beyond simple win/loss assessments.
• It empowers researchers to rescue potentially beneficial therapies or confirm futility, enhancing the evidence base for precision oncology.